CoV2-BMEP and CoV2-TMEP: two novel polyvalent multiepitopic vaccines against SARS-CoV-2
Consejo Superior Investigaciones Científicas (CSIC), Madrid, Spain
Our objective is to design and preclinically evaluate two novel polyvalent multiepitopic immunogens as a long-term SARS-CoV-2 vaccine strategy.
Our proposed asset will contain protective B and T cell epitopes from conserved regions in SARS-CoV-2 Spike (S), Envelope (E), Membrane (M) and nucleocapsid (N) structural proteins when expressed by DNA and MVA vectors. Two DNA components and one poxviral vector co-expressing both antigens (MVA-CoV2B/TMEP) will be generated and delivered.
Our final aim is to establish an effective vaccination strategy that elicits potent and long lasting B and T cell responses that will not only be cross protective across Betacoronaviruses but also elicit resistance to ongoing virus evolution.